Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04424914 · ClinicalTrials.gov registry record · NA
Global Prevalence of ATTR-CM in Participants With HFpEF
A NA study, sponsored by Pfizer.
- Terminated
- Registry status
- NA
- Development phase
- 347
- Enrollment target
NCT04424914: Clinical Trial NA study, sponsored by Pfizer.
NCT04424914 is a NA study that was terminated before completion, run by Pfizer. The registered enrollment target is 347 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04424914, a NA study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- NA
- Development phase
- 347 participants
- Enrollment target
Study Summary
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population \[participants with heart failure with preserved ejection fraction (HFpEF)\].
Primary Outcome
Global prevalence of ATTR-CM in HFpEF participants was obtained by dividing the number of participants who were diagnosed with ATTR-CM in the study by the total number of HFpEF participants evaluated. Diagnosis of ATTR-CM was defined as: cardiac scintigraphy Grade 1, with confirmation of ATTR by cardiac biopsy; or cardiac scintigraphy Grade 2 or above. Exact 95% confidence intervals for the prevalence estimates were calculated using the method of Clopper and Pearson.
Interventions
- DIAGNOSTIC_TEST Scintigraphy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2020-12-30 |
| Est. Completion | 2023-06-02 |
| Phase | NA |
Why NCT04424914 stopped before completion
NCT04424914 is an interventional study that assigns participants to a tested intervention. The registered 347 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Scintigraphy is the first listed.
NCT04424914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04424914 about?
NCT04424914 is a clinical study titled "Global Prevalence of ATTR-CM in Participants With HFpEF". This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population \[participants with heart failure with preserved ejection fraction (HFpEF)\].
What is the current status of trial NCT04424914?
This trial is currently terminated. It is a NA study. The enrollment target is 347 participants. The study started on 2020-12-30. Estimated completion is 2023-06-02.
What interventions are being tested in trial NCT04424914?
The interventions under investigation include: Scintigraphy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04424914?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04424914's enrollment target sits among peer trials
347 302nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
- NCT04877522 · 347 participants · Phase 4
Asciminib Roll-over Study
- NCT05834660 · 347 participants · NA
SAFETY-A for Promoting Equity in Suicide Prevention Outcomes in Schools
- NCT06963827 · 347 participants · Phase 3
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI